Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
Key Highlights
- ➤Ultragenyx agrees to sell Rare Pediatric Disease PRV for $210 million
- ➤PRV proceeds provide non-dilutive capital to advance rare-disease therapies
- ➤Transaction closing requires customary conditions, including Hart-Scott-Rodino waiting-period expiration
- ➤GENGLYCOS approval generated the PRV, marking the first treatment targeting GSDIa’s underlying cause
Expert Statements
Howard Horn, Chief Financial Officer and Executive Vice President, Corporate Strategy of Ultragenyx
“Monetizing this PRV provides significant non-dilutive capital to advance our efforts to bring forward first-ever therapies for rare and ultra-rare diseases, and supports our path to profitability”
Howard Horn, Chief Financial Officer and Executive Vice President, Corporate Strategy of Ultragenyx
“GENGLYCOS itself benefited from capital generated from a previous PRV sale, demonstrating the important role the PRV program plays in helping companies develop transformative therapies for rare disease patients.”
NOVATO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. Ultragenyx received the PRV upon U.S. Food and Drug Administration (FDA) approval of GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, the first treatment designed to address the underlying cause of glycogen storage disease type Ia (GSDIa).
“Monetizing this PRV provides significant non-dilutive capital to advance our efforts to bring forward first-ever therapies for rare and ultra-rare diseases, and supports our path to profitability,” said Howard Horn, chief financial officer and executive vice president, corporate strategy. “GENGLYCOS itself benefited from capital generated from a previous PRV sale, demonstrating the important role the PRV program plays in helping companies develop transformative therapies for rare disease patients.”
Get started
Create a free account to read the full story.